Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 08:27 ET | Source: Pluristyx, Inc.

CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
December 02, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
November 17, 2025 08:55 ET | Source: Research and Markets

$Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034: Top 10 Players Hold 30.52% of 2023 Market, Led by FUJIFILM at 9.24% Share

Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034" report has been added to ResearchAndMarkets.com's offering. ...
November 17, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.
November 13, 2025 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308...
November 13, 2025 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate...
November 05, 2025 07:02 ET | Source: Pluristyx, Inc.

Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics

Pluristyx signs key clinical use licenses for its iPSC platform, enabling new regenerative and neurological disease therapies.
September 24, 2025 10:07 ET | Source: Pluristyx, Inc.

Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions

Pluristyx and Solesis partner to launch game-changing standardized organoid kits, powered by iPSC and polymer technologies.
September 04, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies

Pluristyx & BioLamina partner to accelerate iPSC-based therapies with integrated cell culture solutions, for consistency, scalability & clinical success.
August 22, 2025 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...